[go: up one dir, main page]

US10385079B2 - Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor - Google Patents

Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor Download PDF

Info

Publication number
US10385079B2
US10385079B2 US15/772,521 US201615772521A US10385079B2 US 10385079 B2 US10385079 B2 US 10385079B2 US 201615772521 A US201615772521 A US 201615772521A US 10385079 B2 US10385079 B2 US 10385079B2
Authority
US
United States
Prior art keywords
group
preparation
palladium
ligand
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/772,521
Other versions
US20180319828A1 (en
Inventor
Siyuan Li
Shaoxiao GUI
Jicheng Zhang
Luning Huang
Anping Tao
Hong Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Syncores Technologies Inc Ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Original Assignee
Shanghai Syncores Technologies Inc Ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Syncores Technologies Inc Ltd, Zhejiang Huahai Pharmaceutical Co Ltd filed Critical Shanghai Syncores Technologies Inc Ltd
Assigned to SHANGHAI SYNCORES TECHNOLOGIES INC. LTD., ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD reassignment SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GU, HONG, HUANG, Luning, LI, SIYUAN, TAO, ANPING, ZHANG, JICHENG, GUI, Shaoxiao
Publication of US20180319828A1 publication Critical patent/US20180319828A1/en
Application granted granted Critical
Publication of US10385079B2 publication Critical patent/US10385079B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/02—Sulfur, selenium or tellurium; Compounds thereof
    • B01J27/053—Sulfates
    • B01J27/055—Sulfates with alkali metals, copper, gold or silver
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/08—Halides
    • B01J27/122—Halides of copper
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201—Oxygen-containing compounds
    • B01J31/0211—Oxygen-containing compounds with a metal-oxygen link
    • B01J31/0212—Alkoxylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0237—Amines
    • B01J31/0238—Amines with a primary amino group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2282—Unsaturated compounds used as ligands
    • B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
    • B01J31/30—Halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/40—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the same carbon atom of the carbon skeleton, e.g. amino-ketals, ortho esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/44—Allylic alkylation, amination, alkoxylation or analogues
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Definitions

  • the invention relates to a preparation method for a novel oxazolidinone antibiotic tedizolid or its phosphates, and its intermediate compounds and the preparation method thereof.
  • Tadizolid phosphate has a strong antibacterial activity to pathogens of human and animal, including gram-positive bacteria such as Staphylococcus, Enterococcus and Streptococcus , anaerobic microorganisms such as bacteroid and Clostridium , and acidotolerant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium complex.
  • Tadizolid (formerly called torezolid) was jointly developed by the Cubist Pharmaceuticals company (a subsidiary of Merck Corporation) and Bayer. It was originally found as an antibacterial drug precursor by Dong-A Pharmaceutical (Dong-A ST) and used for the treatment of gram-positive bacterial infections. Tedizolid is rapidly transformed into its active form TR 700 (DA 7157) in plasma.
  • WO2005058886A1 discloses the synthesis of 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidinone, wherein 3-fluoroaniline is used as raw material and reacts with glycidyl butyrate after being protected by Cbz to obtain compound 3.
  • Compound 3 is then iodinated and converted into tin reagent 5, which is Suzuki coupled with 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)-pyridine to produce the key intermediate K.
  • the reaction scheme is depicted as follows:
  • the reaction procedure of the original drug of Dong-A Pharmaceutical is long, and the total yield is not high.
  • relatively expensive reagents such as CF 3 COOAg are needed, and Pd catalyst are needed twice for respectively preparing intermediates 5 and K in the scheme.
  • the reaction conditions are harsh, which is not easy for a large scale production.
  • CN104496979A discloses a method for preparing tedizolid, which is as depicted in the reaction scheme below:
  • R is hydrogen or a hydroxyl protective group; one of L and R 1 is a leaving group, while the other one is BF 3 or BR 2 R 3 , wherein R 2 and R 3 are independently selected from a group consisting of OH, and optionally substituted C 1 -C 6 monohydric alcohol and C 1 -C 6 diol, and wherein R 2 and R 3 can form a ring.
  • Pd is employed in this scheme to catalyze the synthesis of borate intermediate II. After separation and purification, the intermediate II is Suzuki coupled with compound I under catalysis of Pd to obtain the compound of formula H. In this scheme, the reaction operations are complicated, since the intermediate II needs to be separated out before Suzuki coupling.
  • One purpose of the invention is to provide a preparation method of tedizolid, which has low production cost, simple operation, relatively high yield and high purity, and is suitable for industrial production.
  • the invention relates to a novel method for preparing tedizolid by using novel intermediates.
  • the invention provides a method for preparing a tedizolid compound of the formula below
  • the metal catalyst is a copper catalyst.
  • the copper catalyst is preferably selected from a group consisting of Cu powder, CuI, CuBr, Cu 2 O, CuO, Cu 2 O, CuSO 4 , Cu(OAc) 2 or Cu(OTf) 2 , and more preferably CuI and Cu(OAc) 2 .
  • ligands are also required for the reaction.
  • Diamine ligands, diketone ligands, phenanthroline ligands, amino acid ligands, or Phos ligands can be used.
  • the diamine ligands are preferably selected from a group consisting of:
  • the diketone ligands are preferably selected from a group consisting of:
  • the phenanthroline ligands are preferably selected from a group consisting of:
  • amino acid ligands are preferably selected from a group consisting of:
  • the Phos ligands are preferably selected from a group consisting of: X-Phos, XantPhos, RuPhos, BrettPhos, SPhos, DavePhos, JohnPhos and tBuXPhos.
  • the metal catalyst is a palladium catalyst, such as palladium chloride, palladium acetate, tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone)palladium, tetrakis(triphenylphosphine)palladium, dichloro [1,1′-Bis(diphenylphosphino)-ferrocene] palladium, dichlorobis(tricyclohexylphosphine)palladium or dichlorobis(triphenylphosphine)palladium, and preferably, tris-(dibenzylideneacetone)dipalladium, palladium chloride or palladium acetate.
  • a palladium catalyst such as palladium chloride, palladium acetate, tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone)palladium, tetrakis(triphenylpho
  • the reaction can be promoted in alkaline environment (such as potassium acetate, sodium carbonate, potassium carbonate, cesium carbonate, cesium fluoride, sodium hydroxide, potassium hydroxide, potassium phosphate or sodium phosphate, or the like).
  • alkaline environment such as potassium acetate, sodium carbonate, potassium carbonate, cesium carbonate, cesium fluoride, sodium hydroxide, potassium hydroxide, potassium phosphate or sodium phosphate, or the like.
  • the solvent is selected from a group consisting of aromatic hydrocarbons, ethers, alcohols, ethers, nitriles, amides and the like, preferably toluene, chlorobenzene, tetrahydrofuran (THF), N,N-dimethyl-formamide (DMF), dimethyl sulfoxide (DMSO), dioxane, isopropanol, ethanol or acetonitrile; more preferably N,N-dimethylformamide (DMF) and dioxane.
  • the reaction temperature is preferably 60-110° C., and more preferably 90-110° C.
  • the protective group R can be optionally removed (where R is as defined above, excluding hydrogen), to obtain the compound of the formula below:
  • the invention also provides a preparation method of a novel tedizolid intermediate of the formula below:
  • the invention also provides a method for preparing a novel tedizolid intermediate, i.e. the compound of the formula below:
  • R 2 and R 3 are independently selected from a group consisting of OH and C 1 -C 6 monohydric alcohol and C 1 -C 6 diol or C 1 -C 6 monohydric alcohol and C 1 -C 6 diol substituted by halogen, and wherein R 2 and R 3 can form a ring.
  • A is a leaving group
  • B is BF 3 or BR 2 R 3 , wherein R 2 and R 3 can be independently selected from a group consisting of OH and C 1 -C 6 monohydric alcohol and C 1 -C 6 diol or C 1 -C 6 monohydric alcohol and C 1 -C 6 diol substituted by halogen, and wherein R 2 and R 3 can form a ring.
  • B is a leaving group
  • A is BF 3 or BR 2 R 3
  • R 2 and R 3 can be independently selected from a group consisting of OH and C 1 -C 6 monohydric alcohol and C 1 -C 6 diol or C 1 -C 6 monohydric alcohol and C 1 -C 6 diol substituted by halogen, and wherein R 2 and R 3 can form a ring.
  • the leaving groups include halogens such as chlorine, bromine, or iodine, and sulfonyloxy such as trifluoromethane sulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, or benzenesulfonyloxy substituted by one or more substituents, and the substituents are selected from a group consisting of halogen, C 1 -C 6 alkyl and C 1 -C 6 alkoxy; preferably the leaving group is chlorine, bromine or iodine; and more preferably the leaving group is bromine or iodine.
  • halogens such as chlorine, bromine, or iodine
  • sulfonyloxy such as trifluoromethane sulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, or benzenesulfonyloxy substituted by one or more substituent
  • BR 2 R 3 is B(OH) 2 or
  • C is a hydroxyl or amino group; preferably B is bromine or iodine, and A is BF 3 , B(OH) 2 or
  • the catalyst for reaction is palladium catalyst.
  • the palladium catalyst is palladium chloride, palladium acetate, bis(dibenzylideneacetone) palladium, tetrakis(triphenylphosphine) palladium, dichloro[1,1′-bis-(diphenylphosphino)ferrocene] palladium, dichlorobis(tricyclohexylphosphine) palladium or dichlorobis(triphenylphosphine) palladium, or the like.
  • the reaction can be promoted in the presence of alkaline substances, such as potassium carbonate, sodium carbonate, cesium carbonate, cesium fluoride, potassium acetate, sodium hydroxide, potassium hydroxide, potassium phosphate or sodium phosphate.
  • the solvent can be a combination of one or more selected from the group consisting of water, toluene, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, isopropanol, ethanol, acetonitrile, or the like, and preferably toluene, water and dioxane, or isopropanol.
  • the reaction temperature is preferably 50-120° C., and more preferably 70-100° C.
  • C is a hydroxyl or amino group; and preferably A is bromine or iodine, and B is BF 3 , B(OH) 2 or
  • the reaction is carried out preferably in the presence of palladium catalyst.
  • the solvent is preferably water and dioxane, and the reaction temperature is about 60-80° C. Then the tedizolid intermediate compound below is prepared:
  • the invention also provides a novel tedizolid intermediate, i.e. the compound of the chemical formula below:
  • X is a leaving group (the leaving group includes chlorine, bromine, iodine, and sulfonyloxy such as trifluoromethane sulfonyloxy, methane sulfonyloxy, benzene sulfonyloxy, or benzene sulfonyloxy substituted by one or more substituents selected from the group consisting of halogen, C 1 -C 6 alkyl and C 1 -C 6 alkoxy); preferably the leaving group is bromine or iodine.
  • the compound is preferably as follows:
  • the present invention provides a novel method for preparing tedizolid, having the advantages of material availability, low cost, a high yield for each step, simple process, easy operation and environmental friendliness, economical efficiency and being conducive to industrial production.
  • the preparation method of the present invention involves the use of a key intermediate 5-(4-substituent group-2-fluorophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine which allows the preparation scheme of tedizolid being carried out.
  • reaction mixture was warmed to room temperature slowly and reacted for 20 h.
  • the completion of the reaction was monitored by HPLC.
  • the reaction liquid was added into 100 mL ice water dropwise slowly, stirred overnight, and filtered.
  • the solid product was washed with 50 mL to obtain filter cake.
  • the filter cake was oven dried at 65° C. for 20 h and obtained crude white solid, which was then pulped with 40 mL methanol, and filtered.
  • the filter cake was oven dried at 65° C. to obtain 6.8 g pure product of white solid with a yield of 56% and an HPLC purity of 99.7%.
  • the mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, then cooled to 70° C., and filtered under reduced pressure. The filter cake was pulped with DMF (150 mL) for 2 h. The mixture obtained was filtered, and the filter cake was pulped with water (300 mL) again. The mixture obtained was filtered; the filter cake was oven dried at 65° C. to obtain 36.3 g offwhite solid product with a yield of 74.7% and an HPLC purity of 98.3%.
  • the completion of the reaction was monitored by HPLC.
  • the mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure.
  • the filter cake was pulped with DMF (150 mL) for 2 h.
  • the mixture obtained was filtered; and the filter cake was pulped with water (300 mL) again.
  • the mixture obtained was filtered; and the filter cake was oven dried at 65° C. to obtain 39.9 g offwhite solid products with a yield of 82.1% and an HPLC purity of 97.8%.
  • the completion of the reaction was monitored by HPLC.
  • the mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure.
  • the filter cake was pulped with DMF (150 mL) for 2 h.
  • the mixture obtained was filtered; and the filter cake was pulped with water (300 mL) again.
  • the mixture obtained was filtered; and the filter cake was oven dried at 65° C. to obtain 36.7 g offwhite solid product with a yield of 75.5% and an HPLC purity of 98.0%.
  • the completion of the reaction was monitored by HPLC.
  • the mixture obtained was distilled under reduced pressure to remove most of solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure.
  • the filter cake was pulped with DMF (150 mL) for 2 h.
  • the mixture obtained was filtered; and the filter cake was pulped with water (300 mL) again.
  • the mixture obtained was filtered; and the filter cake was oven dried at 65° C. to obtain 36.9 g offwhite solid product with a yield of 76.0% and an HPLC purity of 99.5%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to a preparation method for a tedizolid compound in Formula I. In Formula I, R is selected from hydrogen, formula A, formula B, benzyl or benzyl substituted by a substituent, the substituent is selected from a group consisting of halogen, nitryl, C1-C6 alkyl, and C1-C6 alkoxy, and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen. The method comprises: generating a compound having a structure as shown in Formula C and a compound having a structure as shown in Formula D by a coupled reaction under the catalysis of a metal catalyst, a substituent of R being defined as above, where X is a leaving group, the leaving group comprising chlorine, bromine, iodine, and sulfonyl oxy such as trifluoromethane sulfonic oxy, methylsulfonyl oxy and benzenesulfonyl oxy, or benzenesulfonyl oxy substituted by one or more substituents, the substituent being selected from a group consisting of halogen, C1-C6 alkyl, and C1-C6 alkoxy.
Figure US10385079-20190820-C00001

Description

This application is a national phase application of PCT/CN 2016/104311filed Nov. 2, 2016, which claims priority to Chinese Patent Application No. 20150739910.6 , filed Nov. 3, 2015. The entire contents of those applications are incorporated herein by reference.
TECHNICAL FIELD
The invention relates to a preparation method for a novel oxazolidinone antibiotic tedizolid or its phosphates, and its intermediate compounds and the preparation method thereof.
BACKGROUND ART
Tadizolid phosphate has a strong antibacterial activity to pathogens of human and animal, including gram-positive bacteria such as Staphylococcus, Enterococcus and Streptococcus, anaerobic microorganisms such as bacteroid and Clostridium, and acidotolerant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium complex. Tadizolid (formerly called torezolid) was jointly developed by the Cubist Pharmaceuticals company (a subsidiary of Merck Corporation) and Bayer. It was originally found as an antibacterial drug precursor by Dong-A Pharmaceutical (Dong-A ST) and used for the treatment of gram-positive bacterial infections. Tedizolid is rapidly transformed into its active form TR 700 (DA 7157) in plasma.
WO2005058886A1 discloses the synthesis of 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidinone, wherein 3-fluoroaniline is used as raw material and reacts with glycidyl butyrate after being protected by Cbz to obtain compound 3. Compound 3 is then iodinated and converted into tin reagent 5, which is Suzuki coupled with 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)-pyridine to produce the key intermediate K. The reaction scheme is depicted as follows:
Figure US10385079-20190820-C00002
The reaction procedure of the original drug of Dong-A Pharmaceutical is long, and the total yield is not high. In terms of cost, relatively expensive reagents such as CF3COOAg are needed, and Pd catalyst are needed twice for respectively preparing intermediates 5 and K in the scheme. The reaction conditions are harsh, which is not easy for a large scale production.
Later, the synthetic scheme of the original compound was improved by an licensee Trius Therapeutics company, in whose patent WO2010042887, 4-bromo-3-fluoroaniline is employed as the starting material, first to synthesize boric acid ester 10, which is then Suzuki coupled with 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)-pyridine to generate intermediate 11. Intermediate 11 then reacts with glycidyl butyrate to obtain the oxazolidinone intermediate K. The reaction scheme is depicted as follows:
Figure US10385079-20190820-C00003
Compared with the patented method of Dong-A Pharmaceutical, this scheme is short in reaction procedure with an improved total yield. However, the reaction conditions are still rather harsh. Butyl lithium is needed, and the reaction needs to be carried out at ultra-low temperature (−65° C.). The use of n-BuLi and LiHMDS requires strict anhydrous condition.
In addition, CN104496979A discloses a method for preparing tedizolid, which is as depicted in the reaction scheme below:
Figure US10385079-20190820-C00004
wherein R is hydrogen or a hydroxyl protective group; one of L and R1 is a leaving group, while the other one is BF3 or BR2R3, wherein R2 and R3 are independently selected from a group consisting of OH, and optionally substituted C1-C6 monohydric alcohol and C1-C6 diol, and wherein R2 and R3 can form a ring. Pd is employed in this scheme to catalyze the synthesis of borate intermediate II. After separation and purification, the intermediate II is Suzuki coupled with compound I under catalysis of Pd to obtain the compound of formula H. In this scheme, the reaction operations are complicated, since the intermediate II needs to be separated out before Suzuki coupling.
The methods of prior art for preparing tedizolid intermediates all suffer from complex operation, long reaction time, low total yield and low purity.
SUMMARY OF THE INVENTION
One purpose of the invention is to provide a preparation method of tedizolid, which has low production cost, simple operation, relatively high yield and high purity, and is suitable for industrial production. In particular, the invention relates to a novel method for preparing tedizolid by using novel intermediates.
To achieve the above purpose, the invention provides a method for preparing a tedizolid compound of the formula below
Figure US10385079-20190820-C00005
    • wherein R is selected from a group consisting of hydrogen,
Figure US10385079-20190820-C00006
    •  benzyl or benzyl substituted by a substituent (the substituent is selected from a group consisting of halogen, nitro, C1-C6 alkyl and C1-C6 alkoxy), and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen;
      wherein the method comprises reacting the compound of the formula below
Figure US10385079-20190820-C00007
    • wherein X is a leaving group (the leaving group includes chlorine, bromine, iodine, and sulfonyloxy such as trifluoromethane sulfonyloxy, methane sulfonyloxy, benzenesulfonyloxy, or benzene sulfonyloxy substituted by one or more substituents, and the substituents are selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy; preferably, the leaving group is chlorine, bromine or iodine; and more preferably, the leaving group is bromine or iodine),
      with the compound of the formula below
Figure US10385079-20190820-C00008
by catalysis of a metal catalyst by a coupled reaction, wherein the substituent R is as defined above.
In a preferred embodiment of the present invention, the metal catalyst is a copper catalyst. The copper catalyst is preferably selected from a group consisting of Cu powder, CuI, CuBr, Cu2O, CuO, Cu2O, CuSO4, Cu(OAc)2 or Cu(OTf)2, and more preferably CuI and Cu(OAc)2.
In addition to using a copper catalyst alone, in some instances, ligands are also required for the reaction. Diamine ligands, diketone ligands, phenanthroline ligands, amino acid ligands, or Phos ligands can be used. The diamine ligands are preferably selected from a group consisting of:
Figure US10385079-20190820-C00009
The diketone ligands are preferably selected from a group consisting of:
Figure US10385079-20190820-C00010
The phenanthroline ligands are preferably selected from a group consisting of:
Figure US10385079-20190820-C00011
The amino acid ligands are preferably selected from a group consisting of:
Figure US10385079-20190820-C00012
The Phos ligands are preferably selected from a group consisting of: X-Phos, XantPhos, RuPhos, BrettPhos, SPhos, DavePhos, JohnPhos and tBuXPhos.
In other embodiments of the present invention, the metal catalyst is a palladium catalyst, such as palladium chloride, palladium acetate, tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone)palladium, tetrakis(triphenylphosphine)palladium, dichloro [1,1′-Bis(diphenylphosphino)-ferrocene] palladium, dichlorobis(tricyclohexylphosphine)palladium or dichlorobis(triphenylphosphine)palladium, and preferably, tris-(dibenzylideneacetone)dipalladium, palladium chloride or palladium acetate.
Generally, the reaction can be promoted in alkaline environment (such as potassium acetate, sodium carbonate, potassium carbonate, cesium carbonate, cesium fluoride, sodium hydroxide, potassium hydroxide, potassium phosphate or sodium phosphate, or the like). The solvent is selected from a group consisting of aromatic hydrocarbons, ethers, alcohols, ethers, nitriles, amides and the like, preferably toluene, chlorobenzene, tetrahydrofuran (THF), N,N-dimethyl-formamide (DMF), dimethyl sulfoxide (DMSO), dioxane, isopropanol, ethanol or acetonitrile; more preferably N,N-dimethylformamide (DMF) and dioxane. The reaction temperature is preferably 60-110° C., and more preferably 90-110° C.
When being not
Figure US10385079-20190820-C00013
the protective group R can be optionally removed (where R is as defined above, excluding hydrogen), to obtain the compound of the formula below:
Figure US10385079-20190820-C00014
The compound of the formula above can be further phosphorylated to obtain tedizolid phosphate of the formula below:
Figure US10385079-20190820-C00015
The invention also provides a preparation method of a novel tedizolid intermediate of the formula below:
Figure US10385079-20190820-C00016
    • wherein X is a leaving group as defined above;
      wherein the method includes reacting the compound of the formula below
Figure US10385079-20190820-C00017
    • wherein C is hydroxyl group or amino group;
  • 1) with sulfochloride compounds (such as trifluoroformic anhydride, methanesulfonyl chloride or benzenesulfonyl chloride, or the like), when C is hydroxyl, to obtain the compound of the formula below:
Figure US10385079-20190820-C00018
    • wherein X is a leaving group (the leaving group is sulfonyloxy such as trifluoromethane sulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, or benzenesulfonyloxy substituted by one or more substituents, and the substituents are selected from a group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy);
    • in this circumstance, addition of alkaline substances, such as potassium carbonate, sodium carbonate, cesium carbonate, cesium fluoride, potassium acetate, sodium hydroxide, potassium hydroxide, potassium phosphate, sodium phosphate, or the like, can promote the reaction.
  • 2) to obtain diazonium compounds in the presence of sodium nitrite, when C is amino group, and the diazonium compounds are then substituted by halogen ions to form the compound with of a structure of the formula below:
Figure US10385079-20190820-C00019
    • wherein X is a leaving group, which is selected from a group consisting of chlorine, bromine and iodine;
    • in this circumstance, under acidic conditions such as in the presence of acetic acid, methanesulfonic acid, hydrochloric acid, sulfuric acid or camphosulfonic acid, it is reacted with sodium nitrite to form diazonium. Diazonium is then substituted by halogen ions to obtain the compound of the formula above. Donors of the halogen ions can be chlorine, bromine or iodine. Taking iodine as an example, the donors may include iodine element or Iodide salt such as sodium iodide, potassium iodide, or the like.
The invention also provides a method for preparing a novel tedizolid intermediate, i.e. the compound of the formula below:
Figure US10385079-20190820-C00020
wherein the method includes reacting the compound of the formula below
Figure US10385079-20190820-C00021
with the compound of the formula below
Figure US10385079-20190820-C00022
by catalysis of palladium catalyst by a coupled reaction,
wherein C is a hydroxyl or amino group; one of A and B is a leaving group, and the other one is BF3 or BR2R3, wherein R2 and R3 are independently selected from a group consisting of OH and C1-C6 monohydric alcohol and C1-C6 diol or C1-C6 monohydric alcohol and C1-C6 diol substituted by halogen, and wherein R2 and R3 can form a ring.
In one embodiment, preferably A is a leaving group, B is BF3 or BR2R3, wherein R2 and R3 can be independently selected from a group consisting of OH and C1-C6 monohydric alcohol and C1-C6 diol or C1-C6 monohydric alcohol and C1-C6 diol substituted by halogen, and wherein R2 and R3 can form a ring.
In another embodiment, preferably B is a leaving group, A is BF3 or BR2R3, wherein R2 and R3 can be independently selected from a group consisting of OH and C1-C6 monohydric alcohol and C1-C6 diol or C1-C6 monohydric alcohol and C1-C6 diol substituted by halogen, and wherein R2 and R3 can form a ring.
The leaving groups include halogens such as chlorine, bromine, or iodine, and sulfonyloxy such as trifluoromethane sulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, or benzenesulfonyloxy substituted by one or more substituents, and the substituents are selected from a group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy; preferably the leaving group is chlorine, bromine or iodine; and more preferably the leaving group is bromine or iodine.
Preferably, BR2R3 is B(OH)2 or
Figure US10385079-20190820-C00023
In one embodiment, C is a hydroxyl or amino group; preferably B is bromine or iodine, and A is BF3, B(OH)2 or
Figure US10385079-20190820-C00024
In an embodiment, the catalyst for reaction is palladium catalyst. The palladium catalyst is palladium chloride, palladium acetate, bis(dibenzylideneacetone) palladium, tetrakis(triphenylphosphine) palladium, dichloro[1,1′-bis-(diphenylphosphino)ferrocene] palladium, dichlorobis(tricyclohexylphosphine) palladium or dichlorobis(triphenylphosphine) palladium, or the like.
The reaction can be promoted in the presence of alkaline substances, such as potassium carbonate, sodium carbonate, cesium carbonate, cesium fluoride, potassium acetate, sodium hydroxide, potassium hydroxide, potassium phosphate or sodium phosphate. The solvent can be a combination of one or more selected from the group consisting of water, toluene, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, isopropanol, ethanol, acetonitrile, or the like, and preferably toluene, water and dioxane, or isopropanol. The reaction temperature is preferably 50-120° C., and more preferably 70-100° C.
In another embodiment, C is a hydroxyl or amino group; and preferably A is bromine or iodine, and B is BF3, B(OH)2 or
Figure US10385079-20190820-C00025
In one embodiment, the reaction is carried out preferably in the presence of palladium catalyst. The solvent is preferably water and dioxane, and the reaction temperature is about 60-80° C. Then the tedizolid intermediate compound below is prepared:
Figure US10385079-20190820-C00026
The invention also provides a novel tedizolid intermediate, i.e. the compound of the chemical formula below:
Figure US10385079-20190820-C00027
or the compound of the chemical formula below:
Figure US10385079-20190820-C00028
wherein X is a leaving group (the leaving group includes chlorine, bromine, iodine, and sulfonyloxy such as trifluoromethane sulfonyloxy, methane sulfonyloxy, benzene sulfonyloxy, or benzene sulfonyloxy substituted by one or more substituents selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy); preferably the leaving group is bromine or iodine. The compound is preferably as follows:
Figure US10385079-20190820-C00029
The invention achieves the following technical effects: by comparison with the prior art, the present invention provides a novel method for preparing tedizolid, having the advantages of material availability, low cost, a high yield for each step, simple process, easy operation and environmental friendliness, economical efficiency and being conducive to industrial production. The preparation method of the present invention involves the use of a key intermediate 5-(4-substituent group-2-fluorophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine which allows the preparation scheme of tedizolid being carried out.
DETAILED DESCRIPTION OF THE INVENTION EXAMPLES
In order to make the technical problems solved by the invention, the technical solutions and the beneficial effects more clearly, the invention will be further illustrated in combination with specific examples. The specific examples given are preferred examples of the invention.
Experiments and Data Analysis
Reagents are purchased from commercial sources and they are directly used without treatment. 1H-NMR spectra were measured on a Bruker AVANCE 400 spectrometer operating at 400 MHz. MS data were recorded by Agilent HPLC 1260 Infinity and 6120 Duadrupole LC/MS.
Example 1 Preparation of 2-(2-methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
Figure US10385079-20190820-C00030
5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (20.0 g, 1 eq), bis(pinacolato)-diboron (42.3 g, 2.0 eq), potassium acetate (24.5 g, 3.0 eq) and toluene (400 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (0.6 g, 3% w/w) was added, followed by purging with N2 again, and the mixture was reacted under stirring at 80-85° C. for 12 h. The completion of the reaction was monitored by HPLC. The reaction liquid was cooled to 40-50° C., suction filtered at this temperature. 5 g activated carbon was added to the filtrate. The mixture was then heated to 70-80° C. under stirring for 1-2 h for decoloration, cooled to 40-50° C., and suction filtered at this temperature. The obtained filtrate was distillated under reduced pressure to 40-60 mL, cooled to 10-15° C. to separate out white solid. The white solid was filtered and the filter cake was oven dried at 50° C. to obtain 19.5 g white solid product with a yield of 81.5% and an HPLC purity of 98.5%. LCMS[M+H]=288.1, NMR(CDCl3, 400 MHz): 9.15 (t, 1H), 8. 22(m, 2H), 4.44(s, 3H), 1.25(s, 12H).
Example 2 Preparation of 3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)-aniline
Figure US10385079-20190820-C00031
2-(2-methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (50 g, 1 eq), 4-bromo-3-fluoroaniline (36.4 g, 1.1 eq), Na2CO3 (36.9 g, 2.0 eq), water (300 mL) and dioxane (1000 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (1.5 g, 3% w/w) was added, followed by purging with N2 again, and the mixture was reacted under stirring at 70-80° C. for 12 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the dioxane, added with 500 mL water, stirred at room temperature for 2-3 h; and then filtered. The filter cake was pulped with ethanol (100 mL), and then filtered. The obtained filter cake was oven dried at 50° C. to obtain 42.3 g offwhite solid products with a yield of 90% and an HPLC purity of 99.1%. LCMS[M+H]=271.0, NMR(DMSO-d6, 400 MHz): 9.01(t, 1H), 8.54(s, 2H), 8.18 (m, 2H), 7.75(t, 1H), 7.59 (d, 1H), 7.29 (d, 1H), 4.41(s, 3H).
Example 3 Preparation of 5-(2-fluoro-4-iodophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine
Figure US10385079-20190820-C00032
3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl) pyridin-3-yl)aniline (30.0 g, 1 eq) and acetic acid (600 mL) were added into a three-necked flask equipped with agitator and thermometer, and dissolved under stirring at room temperature. Then, camphorsulfonic acid (30.9 g, 1.2 eq), potassium iodide (36.9 g, 2.0 eq) and sodium nitrite (9.2 g, 1.2 eq) were successively added. The mixture obtained was stirred for 16 h at room temperature. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the acetic acid, then added with 300 mL water and 500 mL dichloromethane, stirred and separated. The dichloromethane layer was washed with water, and then distilled under reduced pressure to remove solvent. 20.8 g brown solid product was obtained with a yield of 49% and an HPLC purity of 96.7%. LCMS[M+H]=381.9, NMR(DMSO-d6, 400 MHz): 8.85(s, 1H), 8.28 (d, 1H), 8.01 (d, 1H), 7.65(t, 1H), 7.56 (dd, 1H), 7.19 (d, 1H), 4.42(s, 3H).
Example 4 Preparation of (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00033
5-(2-fluoro-4-iodophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine (50.0 g, 1 eq), (R)-5-(hydroxymethyl)oxazolidin-2-one (23.0 g, 1.5 eq), cyclohexanediamine (1.5 g, 0.1 eq), cuprous iodide (1.3 g, 0.05 eq), potassium carbonate (36.3 g, 2.0 eq) and dioxane (500 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, the mixture obtained was reacted under stirring at 100-110° C. for 16 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residues, heated to reflux for 1-2 h, then cooled to 70° C., and suction filtered. The filter cake was pulped with DMF (150 mL) for 2 h, and then filtered. The filter cake was pulped again with water (300 mL) and then filtered. The filter cake was oven dried at 65° C. to obtain offwhite solid products with a yield of 79.2% and an HPLC purity of 97.9%. LCMS[M+H]=371.1, NMR (DMSO-d6, 400 MHz): 8.95 (s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78 (t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62 (m, 1H), 4.42 (s, 3H), 3.84 (m, 1H), 3.42-3.35 (m, 2H), 3.01 (m, 1H).
Example 5 Preparation of 3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenol
Figure US10385079-20190820-C00034
2-(2-methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (25 g, 1 eq), 4-bromo-3-fluorophenol (19.9 g, 1.2 eq), Na2CO3 (18.5 g, 2.0 eq), water (120 mL) and dioxane (600 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (0.75 g, 3% w/w) was added, followed by purging with N2 again, and the mixture was reacted under stirring at 70-80° C. for 12 h. The completion of the reaction was monitored by HPLC. The mixture was distilled under reduced pressure to remove most of the dioxane. 500 mL water was added, stirred at room temperature for 2-3 h, and then filtered. The filter cake was pulped with isopropanol (70 mL). The mixture obtained was filtered, and the filter cake was oven dried at 50° C. to obtain 18.2 g white solid product with a yield of 77% and an HPLC purity of 99.5%. LCMS[M+H]=272.0, NMR(DMSO-d6, 400 MHz): 10.20(s, 1H), 9.11(s, 1H), 8.54(d, 1H), 8.18 (d, 1H), 7.75(t, 1H), 7.59 (d, 1H), 7.29 (d, 1H), 4.39(s, 3H).
Example 6 Preparation of 3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl trifluoromethanesulfonate
Figure US10385079-20190820-C00035
3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenol (15 g, 1 eq), trifluoromethanesulfonic anhydride (23.4 g, 1.5 eq), pyridine (6.6 g, 1.5 eq), and tetrahydrofuran (150 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, the mixture obtained was heated to reflux and react for 5 h under stirring. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the tetrahydrofuran. Then, 100 mL ethyl acetate and 100 mL water were added, and stirred at room temperature. Liquids were separated. The organic phase was dried and distilled to remove solvent. 20.0 g white solid product was obtained with a yield of 90% and an HPLC purity of 96.3%. LCMS[M+H]=403.9, NMR(DMSO-d6, 400 MHz): 9.12(s, 1H), 8.44(d, 1H), 8.08 (d, 1H), 7.85 (t, 1H), 7.67 (d, 1H), 7.28 (d, 1H), 4.33(s, 3H).
Example 7 Preparation of (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00036
3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl trifluoromethanesulfonate (10.0 g, 1 eq), (R)-5-(hydroxymethyl)oxazolidin-2-one (3.8 g, 1.3 eq), Pd(dppf)Cl2 (300 mg, 3% w/w), XantPhos (300 mg, 3% w/w), potassium carbonate (6.9 g, 2.0 eq) and dioxane (80 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, the mixture obtained was reacted under stirring at 100-110° C. for 16 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the solvent. The residue was added with 100 mL water, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure. the filter cake was pulped with DMF (150 mL) for 2 h. The obtained mixture was filtered, and the filter cake was pulped with water (150 mL) again. The obtained mixture was filtered, and the filter cake was oven dried at 65° C. to obtain 6.1 g offwhite solid product with a yield of 66% and an HPLC purity of 96.9%. LCMS[M+H]=371.1, NMR(DMSO-d6, 400 MHz): 8.95(s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78(t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62(m, 1H), 4.42(s, 3H), 3.84(m, 1H), 3.42-3.35(m, 2H), 3.01 (m, 1H).
Example 8 Preparation of Tedizolid Phosphate
Figure US10385079-20190820-C00037
(R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxy methyl)-oxazolidin-2-one (10.0 g, 1 eq) and tetrahydrofuran (200 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, the mixture obtained was cooled to 0° C. Triethylamine (8.2 g, 3 eq) was added dropwise. Phosphorus oxychloride was added dropwise at 0-10° C. under stirring. After the addition was completed, the reaction mixture was warmed to room temperature slowly and reacted for 20 h. The completion of the reaction was monitored by HPLC. The reaction liquid was added into 100 mL ice water dropwise slowly, stirred overnight, and filtered. The solid product was washed with 50 mL to obtain filter cake. The filter cake was oven dried at 65° C. for 20 h and obtained crude white solid, which was then pulped with 40 mL methanol, and filtered. The filter cake was oven dried at 65° C. to obtain 6.8 g pure product of white solid with a yield of 56% and an HPLC purity of 99.7%. LCMS[M+H]=451.1, NMR(DMSO-d6, 400 MHz): 8.95(s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78(t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62(m, 1H), 4.42(s, 3H), 3.84(m, 1H), 3.42-3.35(m, 2H), 3.01 (m, 1H).
Example 9 Preparation of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
Figure US10385079-20190820-C00038
4-bromo-3-fluoroaniline (50.0 g, 1 eq), bis(pinacolato)diboron (100.2 g, 1.5 eq), potassium acetate (77.5 g, 3.0 eq) and toluene (500 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (1.5 g, 3% w/w) was added, followed by purging with N2 again, and the mixture was reacted under stirring at 80-85° C. for 8 h. The completion of the reaction was monitored by HPLC. The reaction liquid was cooled to 40-50° C., and filtered under reduced pressure at this temperature. 10 g activated carbon was added to the filtrate. The filtrate was heated to 70-80° C. under stirring for 1-2 h for decoloration, then cooled to 40-50° C., and filtered under reduced pressure at this temperature. The filtrate was distilled under reduced pressure to 80-100 mL, cooled to 10-15° C. to separate out white solid, and filtered. The filter cake was oven dried at 50° C. to obtain 54 g white solid product with a yield of 87% and an HPLC purity of 98.9%. LCMS[M+H]=238.1, NMR(DMSO-d6, 400 MHz): 7.51(d, 1H), 7.02(s, 1H), 6.87(d, 1H), 6.51(s, 2H), 1.25(s, 12H).
Example 10 Preparation of 3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)aniline
Figure US10385079-20190820-C00039
3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)aniline (15 g, 1 eq), 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (18.2 g, 1.2 eq), Na2CO3 (13.4 g, 2.0 eq), water (60 mL) and dioxane (300 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (450 mg, 3% w/w) was added, followed by purging with N2 again. The mixture was reacted under stirring at 70-80° C. for 12 h. The completion of the reaction was monitored by HPLC. The obtained mixture was distilled under reduced pressure to remove most of the dioxane, added with 150 mL water, stirred at room temperature for 2-3 h, and filtered. The filter cake was pulped with ethanol (80 mL). The mixture obtained was filtered, and the filter cake was oven dried at 50° C. to obtain 14.8 g offwhite solid product with a yield of 87% and an HPLC purity of 98.3%. LCMS[M+H]=271.0, NMR(DMSO-d6, 400 MHz): 9.01(t, 1H), 8.54(s, 2H), 8.18 (m, 2H), 7.75(t, 1H), 7.59 (d, 1H), 7.29 (d, 1H), 4.41(s, 3H).
Example 11 Preparation of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
Figure US10385079-20190820-C00040
4-Bromo-3-fluorophenol (30.0 g, 1 eq), bis(pinacolato)diboron (59.8 g, 1.5 eq), potassium acetate (46.3 g, 3.0 eq) and toluene (300 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (0.9 g, 3% w/w) was added, followed by purging with N2 again, and the mixture was reacted under stirring at 80-85° C. for 8 h. The completion of the reaction was monitored by HPLC. The reaction liquid was cooled to 40-50° C., filtered under reduced pressure at this temperature. 10 g activated carbon was added to the filtrate. The filtrate was heated to at 70-80° C. under stirring for 1-2 h for decoloration, then cooled to 40-50° C., and filtered under reduced pressure at this temperature. The filtrate was distilled under reduced pressure to 60-80 mL, cooled to 0-10° C. to separate out white solid, and filtered. The filter cake was oven dried at 50° C. to obtain 29.8 g white solid product with a yield of 80% and an HPLC purity of 99.5%. LCMS[M+H]=239.0, NMR(DMSO-d6, 400 MHz): 10.50(s, 1H), 7.65(d, 1H), 7.42(s, 1H), 7.01(d, 1H), 1.26(s, 12H).
Example 12 Preparation of 3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenol
Figure US10385079-20190820-C00041
3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboran-2-yl)phenol (18.0 g, 1 eq), 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (21.8 g, 1.2 eq), Na2CO3 (16.0 g, 2.0 eq), water (54 mL) and dioxane (270 mL), were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, Pd(dppf)Cl2 (540 mg, 3% w/w) was added, followed by purging with N2 again, and the mixture was reacted under stirring at 70-80° C. for 12 h. The completion of the reaction was monitored by HPLC. The obtained mixture was distilled under reduced pressure to remove most of the dioxane, added with 300 mL water, stirred at room temperature for 2-3 h, and filtered. The filter cake was pulped with isopropanol (90 mL). The obtained mixture was filtered, and the filter cake was oven dried at 50° C. to obtain 16.0 g white solid product with a yield of 78% and an HPLC purity of 98.9%. LCMS[M+H]=272.0, NMR(DMSO-d6, 400 MHz): 10.20(s, 1H), 9.11(s, 1H), 8.54(d, 1H), 8.18 (d, 1H), 7.75(t, 1H), 7.59 (d, 1H), 7.29 (d, 1H), 4.39(s, 3H).
Example 13 Preparation of (R)-2-((benzyloxy)methyl)ethylene oxide
Figure US10385079-20190820-C00042
Benzyl alcohol (50 g, 1 eq), potassium hydroxide aqueous solution 300 mL (50% w/w), TBAB (14.9 g, 0.1 eq) and dichloromethane (300 mL) were added into a three-necked flask equipped with agitator and thermometer, and cooled to 0-10° C. Epoxy chloropropane (64.2 g, 1.5 eq) was added dropwise slowly. After the addition was completed, the mixture obtained was warmed to room temperature and reacted for 16 h. The completion of the reaction was monitored by HPLC. The stir was stopped and the liquids were separated. The aqueous phase was extracted once with 300 mL dichloromethane; and the organic phases were combined and directly used in the next step without purification.
Example 14 Preparation of (R)-1-amino-3-(benzyloxy)isopropanol
Figure US10385079-20190820-C00043
A solution of (R)-2-((benzyloxy)methyl)oxirane in dichloromethane and 100 mL aqueous ammonia were added into a hydrogenated bottle equipped with agitator, heated to 35° C. after sealing, stirred and reacted for 16 h. The completion of the reaction was monitored by HPLC. The stir was stopped, and 300 mL water was added, and stirred. The liquids were separated. The organic phase was washed with 0.1M HCl solution (100 mL), and dichloromethane was separated and discarded. The aqueous phase was adjusted with NaOH to pH 9-10, extracted with (300 mL) dichloromethane and concentrated to obtain 55.0 g colorless liquid product, with a two-step yield of 66% and an HPLC purity of 98.4%. LCMS[M+H]=182.0, NMR(DMSO-d6, 400 MHz): 7.42-7.25(m, 5H), 5.11(s, 2H), 4.54(s, 2H), 3.68 (m, 1H), 3.50-3.34(m, 2H), 3.12-3.06 (br, 1H), 3.00-2.89 (m, 2H).
Example 15 Preparation of (R)-5-((benzyloxy)methyl)oxazolidin-2-one
Figure US10385079-20190820-C00044
(R)-1-amino-3-(benzyloxy)isopropanol (20 g, 1 eq) and tetrahydrofuran (200 mL) were added into a three-necked flask equipped with agitator, heated to 35° C., added with CDI (26.8 g, 1.5 eq). The obtained mixture was stirred and reacted for 16 h while keeping the temperature. The completion of the reaction was monitored by HPLC. The stir was stopped and the tetrahydrofuran-containing solution was concentrated. 200 mL ethyl acetate and 100 mL 1M hydrochloric acid were added, and stirred. The liquids were separated. The organic phase was washed with water and the ethyl acetate-containing phase was concentrated to obtain a colorless liquid product 21.0 g with yield of 92% and HPLC purity of 99.0%. LCMS[M+H]=208.0, NMR(DMSO-d6, 400 MHz): 8.05(s, 1H), 7.44-7.22(m, 5H), 4.56(s, 2H), 4.28-4.20 (m, 1H), 3.77-3.69(m, 1H), 3.42-3.29 (m, 2H), 3.11-3.06 (m, 1H).
Example 16 Preparation of (R)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00045
(R)-5-((benzyloxy)methyl)oxazolidin-2-one (15 g, 1 eq), tetrahydrofuran (150 mL) and Pd/C (1.5 g, 10% w/w) were added into a three-necked flask equipped with agitator. After purging with H2, the mixture obtained was heated to 45° C., stirred and reacted for 3 h by keeping this temperature. The completion of the reaction was monitored by HPLC. The mixture obtained was filtered without stir to remove Pd/C. The tetrahydrofuran-containing phase was concentrated to obtain 8.4 g colorless oil product with a yield of 99% and an HPLC purity of 98.6%. LCMS[M+H]=117.9, NMR(DMSO-d6, 400 MHz): 7.92(s, 1H), 4.68-4.60 (m, 1H), 3.97-3.90(m, 1H), 3.70 (br, 1H), 3.62-3.55 (m, 2H), 3.11-3.06 (m, 1H).
Example 17 Preparation of (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00046
5-(2-fluoro-4-iodophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine (50.0 g, 1 eq), (R)-5-(hydroxymethyl) oxazolidin-2-one (23.0 g, 1.5 eq), cyclohexanediamine (1.5 g, 0.1 eq), copper sulfate (1.05 g, 0.05 eq), potassium carbonate (36.3 g, 2.0 eq) and dioxane (500 mL) were added into a three-necked flask equipped with agitator and thermometer. The mixture obtained was stirred and reacted at 100-110° C. for 16 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, then cooled to 70° C., and filtered under reduced pressure. The filter cake was pulped with DMF (150 mL) for 2 h. The mixture obtained was filtered, and the filter cake was pulped with water (300 mL) again. The mixture obtained was filtered; the filter cake was oven dried at 65° C. to obtain 36.3 g offwhite solid product with a yield of 74.7% and an HPLC purity of 98.3%. LCMS[M+H]=371.1, NMR(DMSO-d6, 400 MHz): 8.95(s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78(t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62(m, 1H), 4.42(s, 3H), 3.84(m, 1H), 3.42-3.35(m, 2H), 3.01 (m, 1H).
Example 18 Preparation of (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00047
5-(2-fluoro-4-iodophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine (50.0 g, 1 eq), (R)-5-(hydroxymethyl) oxazolidin-2-one (23.0 g, 1.5 eq), cyclohexanediamine (1.5 g, 0.1 eq), Cu(OAc)2 (1.19 g, 0.05 eq), potassium carbonate (36.3 g, 2.0 eq) and dioxane (500 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, the mixture obtained was stirred and reacted at 100-110° C. for 16 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure. The filter cake was pulped with DMF (150 mL) for 2 h. The mixture obtained was filtered; and the filter cake was pulped with water (300 mL) again. The mixture obtained was filtered; and the filter cake was oven dried at 65° C. to obtain 39.9 g offwhite solid products with a yield of 82.1% and an HPLC purity of 97.8%. LCMS[M+H]=371.1, NMR(DMSO-d6, 400 MHz): 8.95(s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78(t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62(m, 1H), 4.42(s, 3H), 3.84(m, 1H), 3.42-3.35(m, 2H), 3.01 (m, 1H).
Example 19 Preparation of (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00048
5-(2-fluoro-4-iodophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine (50.0 g, 1 eq), (R)-5-(hydroxymethyl) oxazolidin-2-one (23.0 g, 1.5 eq), cyclohexanediamine (1.5 g, 0.1 eq), tris(dibenzylideneacetone)dipalladium (1.5 g, 3% w/w), potassium carbonate (36.3 g, 2.0 eq) and dioxane (500 mL) were added into a three-necked flask equipped with agitator and thermometer. The mixture obtained was stirred and reacted at 100-110° C. for 16 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of the solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure. The filter cake was pulped with DMF (150 mL) for 2 h. The mixture obtained was filtered; and the filter cake was pulped with water (300 mL) again. The mixture obtained was filtered; and the filter cake was oven dried at 65° C. to obtain 36.7 g offwhite solid product with a yield of 75.5% and an HPLC purity of 98.0%. LCMS[M+H]=371.1, NMR(DMSO-d6, 400 MHz): 8.95(s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78(t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62(m, 1H), 4.42(s, 3H), 3.84(m, 1H), 3.42-3.35(m, 2H), 3.01 (m, 1H).
Example 20 Preparation of (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridyl-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Figure US10385079-20190820-C00049
5-(2-fluoro-4-iodophenyl)-2-(2-methyl-2H-tetrazol-5-yl)pyridine (50.0 g, 1 eq), (R)-5-(hydroxymethyl) oxazolidin-2-one (23.0 g, 1.5 eq), cyclohexanediamine (1.5 g, 0.1 eq), cuprous iodide (1.3 g, 0.05 eq), potassium carbonate (36.3 g, 2.0 eq) and DMF (500 mL) were added into a three-necked flask equipped with agitator and thermometer. After purging with N2, the mixture obtained was stirred and reacted at 100-110° C. for 16 h. The completion of the reaction was monitored by HPLC. The mixture obtained was distilled under reduced pressure to remove most of solvent. 1000 mL water was added into the residue, heated to reflux for 1-2 h, cooled to 70° C., and filtered under reduced pressure. The filter cake was pulped with DMF (150 mL) for 2 h. The mixture obtained was filtered; and the filter cake was pulped with water (300 mL) again. The mixture obtained was filtered; and the filter cake was oven dried at 65° C. to obtain 36.9 g offwhite solid product with a yield of 76.0% and an HPLC purity of 99.5%. LCMS[M+H]=371.1, NMR(DMSO-d6, 400 MHz): 8.95(s, 1H), 8.24 (d, 1H), 8.10 (d, 1H), 7.78(t, 1H), 7.45 (dd, 1H), 7.10 (d, 1H), 4.62(m, 1H), 4.42(s, 3H), 3.84(m, 1H), 3.42-3.35(m, 2H), 3.01 (m, 1H).
The description above was only preferred embodiments of the present invention, which is not limited thereto. Any modification, substitution and improvement made within the spirit and scope of the present invention should fall into the scope claimed by the present invention.

Claims (8)

What is claimed is:
1. A preparation method for tedizolid compound of the formula below
Figure US10385079-20190820-C00050
wherein R is selected from the group consisting of hydrogen,
Figure US10385079-20190820-C00051
benzyl and benzyl substituted by a substituent selected from the group consisting of halogen, nitro, C1-C6 alkyl and C1-C6 alkoxy, and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen;
wherein the preparation method comprises reacting the compound having a structure of the formula below
Figure US10385079-20190820-C00052
wherein X is a leaving group selected from the group consisting of chlorine, bromine, iodine, and sulfonyloxy;
with the compound having a structure of the formula below
Figure US10385079-20190820-C00053
under the catalysis of metal catalyst in the presence of an alkaline substance as a promoter, in a reaction solvent selected from the group consisting of toluene, chlorobenzene, tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide, dioxane, isopropanol, ethanol and acetonitrile, at a reaction temperature of 60-110° C. to produce the tedizolid compound by a coupled reaction, and wherein substituent R is as defined above.
2. The preparation method according to claim 1, wherein the metal catalyst is a copper catalyst or a palladium catalyst.
3. The preparation method according to claim 1, wherein when the metal catalyst is a copper catalyst, the copper catalyst acts together with ligands selected from the group consisting of a diamine ligand, a diketone ligand, a phenanthroline ligand, an amino acid ligand, and a Phos ligand.
4. The preparation method according to claim 1, wherein the sulfonyloxy is selected from the group consisting of trifluoromethane sulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, and benzenesulfonyloxy substituted by one or more substituent(s) selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy.
5. The preparation method according to claim 2, wherein the copper catalyst is selected from the group consisting of CuI, CuBr, CuCl, CuO, Cu2O, CuSO4, Cu(OAc)2, Cu(OTf)2 and Cu powder; and/or the palladium catalyst is selected from the group consisting of palladium chloride, palladium acetate, bis(dibenzylideneacetone) palladium, tetrakis(triphenylphosphine) palladium, tris(dibenzylideneacetone) dipalladium, dichloro [1, 1′-bis(diphenylpho sphino)ferrocene] palladium, dichlorobis(tricyclohexylphosphine) palladium and dichlorobis(triphenylphosphine) palladium.
6. The preparation method according to claim 1, wherein the alkaline substance is selected from the group consisting of potassium carbonate, sodium carbonate, cesium carbonate, cesium fluoride, potassium acetate, sodium hydroxide, potassium hydroxide, potassium phosphate and sodium phosphate.
7. The preparation method according to claim 1, wherein the reaction temperature is 90-110° C.
8. The preparation method according to claim 3, wherein the diamine ligand is selected from the group consisting of:
Figure US10385079-20190820-C00054
the diketone ligand is selected from the group consisting of:
Figure US10385079-20190820-C00055
the phenanthroline ligand is selected from the group consisting of:
Figure US10385079-20190820-C00056
the amino acid ligand is
Figure US10385079-20190820-C00057
and the Phos ligand is selected from the group consisting of X-Phos, XantPhos, RuPhos, BrettPhos, SPhos, DavePhos, JohnPhos and tBuXPhos.
US15/772,521 2015-11-03 2016-11-02 Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor Active US10385079B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201510739910.6A CN106632298B (en) 2015-11-03 2015-11-03 Preparation method and intermediate of tedizolid
CN201510739910 2015-11-03
CN201510739910.6 2015-11-03
PCT/CN2016/104311 WO2017076285A1 (en) 2015-11-03 2016-11-02 Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor

Publications (2)

Publication Number Publication Date
US20180319828A1 US20180319828A1 (en) 2018-11-08
US10385079B2 true US10385079B2 (en) 2019-08-20

Family

ID=58661614

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/772,521 Active US10385079B2 (en) 2015-11-03 2016-11-02 Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor
US15/771,449 Active US10590154B2 (en) 2015-11-03 2016-11-02 Method for preparing oxazolidinone intermediate

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/771,449 Active US10590154B2 (en) 2015-11-03 2016-11-02 Method for preparing oxazolidinone intermediate

Country Status (4)

Country Link
US (2) US10385079B2 (en)
EP (2) EP3372596B1 (en)
CN (3) CN106632298B (en)
WO (2) WO2017076285A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383807B (en) * 2018-04-12 2020-10-27 深圳市前海博扬研究院有限公司 Method for reducing discharge of salt-containing wastewater of etherification reaction
CN110938058B (en) * 2018-09-22 2022-04-12 南京优科生物医药研究有限公司 Preparation method of oxazolidinone antibiotic intermediate
CN111116652A (en) * 2019-12-06 2020-05-08 山东中医药大学 A kind of preparation method of high-purity tedizolid phosphate
CN111514935B (en) * 2020-04-30 2022-11-15 中国工程物理研究院化工材料研究所 Self-ignition catalyst for energetic ionic liquid-hydrogen peroxide and preparation method thereof
BR112022025918A2 (en) 2020-06-18 2023-03-14 Akagera Medicines Inc OXAZOLIDINONE COMPOUNDS, LIPOSOMAL COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF
CN114105946A (en) * 2020-08-26 2022-03-01 浙江苏泊尔制药有限公司 A kind of tedizolid phosphate intermediate and preparation method thereof
CN113354620B (en) 2021-07-05 2022-03-22 南京桦冠生物技术有限公司 Efficient preparation method of tedizolid intermediate and intermediate thereof
CN113620897A (en) * 2021-09-06 2021-11-09 南京杰运医药科技有限公司 Preparation method of oxazolidinone compound
CN115792047B (en) * 2023-02-10 2023-05-19 四川美域高生物医药科技有限公司 Method for detecting related substances of tedizolid phosphate intermediate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056818A1 (en) 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial
WO2005058886A1 (en) 2003-12-18 2005-06-30 Dong-A Pharm.Co.,Ltd. Novel oxazolidinone derivatives
WO2010042887A2 (en) 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
CN104327119A (en) 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 Preparation method of tedizolid phosphate
CN104496979A (en) 2014-09-17 2015-04-08 博瑞生物医药技术(苏州)有限公司 Method for preparing oxazolidinone compound and intermediate thereof
CN104892592A (en) 2015-03-30 2015-09-09 成都惟新医药科技有限公司 Preparation method for tedizolid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403804B1 (en) * 1998-12-07 2002-06-11 Takasago International Corporation Process for preparing optically active oxazolidinone derivative
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CN102850288A (en) * 2011-06-28 2013-01-02 袁建勇 Method for preparing linezolid
US8889671B2 (en) * 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
CN103304594B (en) * 2013-06-18 2015-07-08 上海科利生物医药有限公司 Preparation method of L-alpha-glycerophosphoryl choline

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056818A1 (en) 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial
WO2005058886A1 (en) 2003-12-18 2005-06-30 Dong-A Pharm.Co.,Ltd. Novel oxazolidinone derivatives
WO2010042887A2 (en) 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
US9328087B2 (en) * 2008-10-10 2016-05-03 Merck Sharp & Dohme Corp. Methods for preparing oxazolidinones and compositions containing them
CN104496979A (en) 2014-09-17 2015-04-08 博瑞生物医药技术(苏州)有限公司 Method for preparing oxazolidinone compound and intermediate thereof
CN104327119A (en) 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 Preparation method of tedizolid phosphate
CN104892592A (en) 2015-03-30 2015-09-09 成都惟新医药科技有限公司 Preparation method for tedizolid

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 26 August 2016 (2016-08-26), DESI REDDY, SRINIVAS REDDY ET AL.: "A novel process for the preparation of Tedizolid", XP002789889, retrieved from STN
Database CA, Chemical Abstracts Service, Columbus, Ohio, US; Aug. 26, 2016, Desi Reddy, Srinivas Reddy et al.: "A novel process for the preparation of Tedizolid", XP002789889.
Desi Reddy, Srinivas Reddy et al.: "IN2014CH05297: a novel process for the preparation of Tedizolid", Aug. 26, 2016, pp. 1-25, XP055571801.
EP Search Report of European Application No. 16 86 1553.
International Search Report of International Application No. PCT/CN2016/104330, filed Nov. 2, 2016.

Also Published As

Publication number Publication date
CN106632298A (en) 2017-05-10
EP3372596B1 (en) 2020-07-22
EP3372597A1 (en) 2018-09-12
EP3372596A1 (en) 2018-09-12
CN108430999A (en) 2018-08-21
CN108368100A (en) 2018-08-03
CN108368100B (en) 2021-07-23
CN106632298B (en) 2021-06-01
CN108430999B (en) 2021-07-23
WO2017076285A1 (en) 2017-05-11
EP3372597A4 (en) 2019-08-28
US20180319828A1 (en) 2018-11-08
WO2017076293A1 (en) 2017-05-11
EP3372596A4 (en) 2019-05-08
US10590154B2 (en) 2020-03-17
US20180312476A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
US10385079B2 (en) Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor
EP2552893B1 (en) Antibacterial isoquinolin-3-ylurea derivatives
CN101774978B (en) Preparation method of linezolid and intermediate thereof
EP2481742B1 (en) Preparation method of aromatic boronate compounds
US10280145B2 (en) Urea derivative and use therefor
CN103391927A (en) Novel process for preparation of linezolid and its novel intermediates
CN104402946A (en) Invokana intermediate and preparation method thereof in amorphous form
US9815829B2 (en) Process for the preparation of optically active isoxazoline compounds
CN110938058B (en) Preparation method of oxazolidinone antibiotic intermediate
CN105418678B (en) A kind of preparation method of Tedizolid Phosphate
JP7405967B2 (en) Efficient method for preparing tedizolid intermediate and its intermediate
CN101585816B (en) Benzene sulfonamide hydroxyl derivative and intermediate thereof as well as preparation method and application thereof
US20220056027A1 (en) Pharmaceutical process and intermediates
CA2812910A1 (en) Method of preparing benzoimidazole derivatives
CN115385959B (en) High-purity tedizolid phosphate and preparation method thereof
US20130109862A1 (en) Methods for preparing intermediates of perampanel
US9643905B2 (en) Phenylnaphthol derivatives
CN110016029B (en) Preparation method of 3-fluoro-1H-pyrrolo [2,3-b ] pyridine-2-carboxylic acid
CN105837633A (en) Preparation method of antimicrobial compound
CN105566392B (en) A kind of preparation method of bacterio protein synthetic inhibitor
CN102442947A (en) Preparation method of Montelukast Sodium intermediate
US8802860B2 (en) Method for producing substituted pyridin-2-one
CN105503955B (en) A kind of preparation method of the compound of resisting gram-positive bacteria
JP4568824B2 (en) Method for producing diarylsulfonic acid derivative
CN104610229B (en) Synthesis method of ATP competitive small-molecule AKT inhibitor A443654

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, SIYUAN;GUI, SHAOXIAO;ZHANG, JICHENG;AND OTHERS;SIGNING DATES FROM 20180424 TO 20180425;REEL/FRAME:045686/0627

Owner name: SHANGHAI SYNCORES TECHNOLOGIES INC. LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, SIYUAN;GUI, SHAOXIAO;ZHANG, JICHENG;AND OTHERS;SIGNING DATES FROM 20180424 TO 20180425;REEL/FRAME:045686/0627

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4